Biotech Values

[DewDiligence]

(BMY)—TRNG.PA +5% on phase-2 trial to test TG4010 + Opdivo + chemo in first-line non-squamous NSCLC patients with low or undetectable PDL-1 expression:

http://finance.yahoo.com/news/transgene-bristol-myers-squibb-announce-053000038.html

The Phase 2 clinical trial will explore the potential of combining Transgene’s TG4010, an investigational therapeutic vaccine designed to generate an immune response against MUC1 expressing tumors such as NSCLC, in conjunction with Bristol-Myers Squibb’s immune checkpoint inhibitor, Opdivo, designed to alleviate immune suppression. Both therapies will be combined with standard chemotherapy in first line NSCLC patients. The Phase 2 trial will evaluate objective tumor responses, and disease control in patients provided the regimen of TG4010 + Opdivo + CT, whose tumors express low and undetectable levels of PD-L1. …This multi-center single-arm trial is expected to deliver first results in 2018.

TRNG.PA is conducting the trial; BMY is merely supplying free Opdivo.